News & Alerts
-
Dec- 2023 -4 December
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix Pharmaceuticals Limited (ASX: TLX) has revealed a significant development in its investigational positron emission tomography (PET) imaging agent, TLX250-CDx,…
Read More » -
1 December
Federal Court Orders Puerto Rico Pharmaceutical Distributor to Pay $12 Million Over Controlled Substance Violations
A federal court in Puerto Rico entered a consent decree requiring Droguería Betances LLC (Betances), one of Puerto Rico’s largest…
Read More » -
1 December
Eitan Medical Ltd Recalls Sapphire Infusion Pumps for Failure to Detect Air in the Line
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices…
Read More » -
Nov- 2023 -30 November
Meta Herbal Issues Voluntary Nationwide Recall of Magnum XXL 9800 Capsules Due to Presence of Undeclared Sildenafil
Meta Herbal is voluntarily recalling 500 blister packs of Magnum XXL 9800 2000 mg per capsule, to the consumer level.…
Read More » -
30 November
The US FDA Is Evaluating Plastic Syringes Made in China for Potential Device Failures
The U.S. Food and Drug Administration (FDA) is informing consumers, healthcare providers, and health care facilities that the FDA is…
Read More » -
30 November
Too Sick to Work? Expert Weighs the Decision
You’re sniffling, sneezing, and your nose is running like a faucet. It’s about that time of year when people everywhere…
Read More » -
30 November
Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR
DelveInsight’s recent Market Insights report on Metastatic HER2-Positive Breast Cancer provides a comprehensive analysis of current treatment practices, emerging drugs,…
Read More » -
30 November
Pharmaceutical Contract Research and Manufacturing Market size is set to grow by USD 121.35 billion from 2022-2027
According to a recent report by Technavio, the Pharmaceutical Contract Research and Manufacturing Market is poised to witness significant growth,…
Read More » -
30 November
Astellas’ Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Astellas Pharma Inc. (TSE: 4503) is set to present 24-week results from the Phase 3b DAYLIGHT clinical trial at the…
Read More » -
29 November
FDA Investigating Serious Risk of T-cell Malignancy, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
AUDIENCE: Patient, Health Professional, Risk Manager, Oncology, Pharmacy ISSUE: The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive…
Read More »